Efficacy and safety of deferiprone for the treatment of superficial siderosis: results from a long-term observational study

• DOI: 10.1007/s10072-019-03847-x
• Publication Date: 2019-03-22T23:02:17Z
• Authors: Giovanni Cossu; Giovanni Abbruzzese; Gian Luca Forni; Gildo Matta; Valeria Pinto; Uberto Ruffinengo; Valentina Oppo; Roberta Marchese
• Keywords: Superficial siderosis; Deferiprone; Siderosis; Hemosiderin; Neuroradiology

Superficial siderosis (SS) of the central nervous system is a rare and heterogeneous condition due to deposition of hemosiderin on the surface of the brain and spinal cord. The usually progressive clinical course is characterized by a combination of hearing loss, cerebellar ataxia, and myelopathy. There is no known treatment for SS, but the iron chelator deferiprone (DFP) has been proposed as a potentially useful treatment.We present a long-term (average 3.7 years) evaluation of four cases of SS treated with DFP (15 mg/kg po bid).Treatment with DFP proved safe and well tolerated. Two out of the four subjects were unchanged while the other two presented a clinical improvement with reduction of postural instability and cerebellar signs. Blinded evaluation of magnetic resonance imaging (performed every 6 months during follow-up) showed a reduction of the abnormal iron deposition for all patients.This long-term observational study suggests that DFP may be effective in the management of the neurological manifestations associated with iron accumulation in SS. CLINICALTRIALS.NTC00907283.